Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue The Motley Fool
Covered in this story
Analyst targets on Bristol Myers Squibb
- Wells Fargo: $57.6 → $60 by Oct 2027 · Equal Weight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BMY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bristol Myers Squibb →Dalsna Finance is currently tracking 5 stories mentioning Bristol Myers Squibb, the earliest published 20 Oct 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.